Faron Pharmaceuticals Oy (FARN.L)
GBp 175.0
(2.94%)
GBp 175.0
(2.94%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.8 Million | -22.99 Million | -22.21 Million | -17.47 Million | -11.52 Million | -20.52 Million |
| Net Income | -30.94 Million | -28.73 Million | -21.19 Million | -16.93 Million | -13.25 Million | -20.08 Million |
| Depreciation & Amortization | 346 Thousand | 300 Thousand | 307 Thousand | 283 Thousand | 238 Thousand | 100 Thousand |
| Deferred income taxes | -1.25 Million | - | 114 Thousand | 98 Thousand | -56 Thousand | -65 Thousand |
| Stock-based compensation | 2.45 Million | 1.29 Million | 1.48 Million | 386 Thousand | 51 Thousand | -176 Thousand |
| Change in working capital | 3.24 Million | 4.76 Million | -1.76 Million | -872 Thousand | 1.33 Million | -421 Thousand |
| Other non-cash items | 2.35 Million | -626 Thousand | -1.17 Million | -438 Thousand | 158 Thousand | 121 Thousand |
| Investing Cash Flow | -123 Thousand | -385 Thousand | -473 Thousand | -142 Thousand | -100 Thousand | -295 Thousand |
| Investments in PPE | -123 Thousand | -385 Thousand | -474 Thousand | -142 Thousand | -100 Thousand | -295 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -123.00 | -385.00 | 1000.00 | -137.00 | -100.00 | -293.00 |
| Financing Cash Flow | 23.98 Million | 23.47 Million | 25.59 Million | 14.78 Million | 14.6 Million | 15.54 Million |
| Debt repayment | -861 Thousand | -105 Thousand | -122 Thousand | -122 Thousand | -151.00 | -347 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 26.03 Million | 13.44 Million | 25.55 Million | 14.1 Million | 15.62 Million | 17.02 Million |
| Other Financing Activities | 81 Thousand | 10.13 Million | 153 Thousand | 806 Thousand | -1.01 Million | -1.13 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 3.24 Million | 4.76 Million | -1.76 Million | -872 Thousand | 1.33 Million | -759.00 |
| Cash at beginning of period | 6.99 Million | 6.85 Million | 4.1 Million | 7.05 Million | 4.06 Million | 9.31 Million |
| Cash at end of period | 6.87 Million | 6.99 Million | 6.85 Million | 4.1 Million | 7.05 Million | 4.06 Million |
| Capital Expenditure | -123 Thousand | -385 Thousand | -474 Thousand | -142 Thousand | -100 Thousand | -295 Thousand |
| Effect of forex changes on cash | -168 Thousand | 37 Thousand | -153 Thousand | -117 Thousand | 7000.00 | 36 Thousand |
| Net cash flow / Change in cash | -114 Thousand | 137 Thousand | 2.74 Million | -2.95 Million | 2.99 Million | -5.24 Million |
| Free Cash Flow | -23.92 Million | -23.37 Million | -22.69 Million | -17.62 Million | -11.62 Million | -20.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -7197.50 | -7197.50 | -30.94 Million | -8607.00 | -8607.00 | -6865.00 |
| Depreciation & Amortization | 79.00 | 79.00 | 346 Thousand | 86.00 | 86.00 | 87.00 |
| Deferred income taxes | - | - | -1.25 Million | - | - | 584.09 Thousand |
| Stock-based compensation | 184.50 | 184.50 | 2.45 Million | 980.50 | 980.50 | 244.50 |
| Change in working capital | -1360.00 | -1360.00 | 3.24 Million | -253.00 | -253.00 | 378.00 |
| Other non-cash items | 3947.50 | 3947.50 | 2.35 Million | 2062.00 | 2062.00 | -16.00 |
| Investing Cash Flow | -61.50 | -61.50 | -123 Thousand | -27.50 | -27.50 | -34.00 |
| Investments in PPE | - | - | -123 Thousand | - | - | -58.43 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -61.50 | -61.50 | -123.00 | -27.50 | -27.50 | -34.00 |
| Financing Cash Flow | 15.88 Thousand | 15.88 Thousand | 23.98 Million | 6096.00 | 6096.00 | 5895.50 |
| Debt repayment | - | - | -861 Thousand | - | - | -54.99 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 26.03 Million | - | - | 9.82 Million |
| Other Financing Activities | 15.88 Thousand | 15.88 Thousand | 81 Thousand | 6096.00 | 6096.00 | 5895.50 |
| Accounts receivables | - | - | - | - | - | 883.38 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -1360.00 | -1360.00 | 3.24 Million | -253.00 | -253.00 | 378.00 |
| Cash at beginning of period | -0.50 | - | 6.99 Million | - | - | 6.18 Million |
| Cash at end of period | 11.4 Thousand | 11.4 Thousand | 6.87 Million | 280.50 | 280.50 | 5.42 Million |
| Capital Expenditure | - | - | -123 Thousand | - | - | -58.43 Thousand |
| Effect of forex changes on cash | -72.50 | -72.50 | -168 Thousand | -56.50 | -56.50 | -27.50 |
| Net cash flow / Change in cash | 11.4 Thousand | 11.4 Thousand | -114 Thousand | 280.50 | 280.50 | -759.12 Thousand |
| Free Cash Flow | -4346.50 | -4346.50 | -23.92 Million | -5731.50 | -5731.50 | -64.6 Thousand |
BLMN
NARMADA
PEN
ECLERX
0JCB
ALTN